Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
Tesla: The Thesis Is Stronger Than Ever
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BLCO Stock News and Mentions of Bausch + Lomb Corporation Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Bausch + Lomb Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Bausch + Lomb Corporation (BLCO).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Bausch + Lomb stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Bausch + Lomb Corporation (BLCO)
May 2, 2024 (17:48) / "Benzinga" (by Nabaparna Bhattacharya)
Why Bausch Health Companies Shares Are Falling After Q1 Results - Bausch Health Companies ( NYSE:BHC )
Bausch Health Companies Inc. BHC shares are trading lower on Thursday after reporting first-quarter results. The company reported adjusted quarterly earnings per share of 59 cents, missing the street view of 72 cents. Sales of $2.153 billion marginally missed the analyst consensus of $2.156 ...
In Article Trend: Somewhat-Bullish
May 1, 2024 (10:44) / "Benzinga" (by Shanthi Rexaline)
Nasdaq, S&P 500 Futures Signal Weaker Open As Fed Decision Looms: What's Going On With Markets? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.'s AMD underwhelming quarterly report, exerting pressure on the tech sector and the broader market.
In Article Trend: Neutral
April 29, 2024 (05:51) / "Benzinga" (by Shanthi Rexaline)
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Corporate earnings came to the market's rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it remains to be seen whether the tech earnings deluge can keep the rally's momentum going.
In Article Trend: Somewhat-Bullish
April 25, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Preview: Alignment Healthcare ( ALHC ) Q1 Earnings Expected to Decline
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Bausch + Lomb ( BLCO ) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 22, 2024 (05:30) / "GlobeNewswire" (by NICOX SA)
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
Income statement ...
In Article Trend: Neutral
April 15, 2024 (07:12) / "PR Newswire"
Optical Biometry Devices Market size is set to grow by USD 93.26 million from 2023-2027, Rise in prevalence of ... - PR Newswire
Optical Biometry Devices Market size is set to grow by USD 93.26 million from 2023-2027, Rise in prevalence of ... PR ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb ( BLCO Quick QuoteBLCO - ) and Avantor, Inc. ( AVTR Quick QuoteAVTR - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
In Article Trend: Bullish
April 3, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Bausch Health ( BHC ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
April 2, 2024 (12:44) / "Investing News Network" (by Investing News Network)
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find ... Investing News Network ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
All You Need to Know About Bausch + Lomb ( BLCO ) Rating Upgrade to Buy
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
BLCO or AVTR: Which Is the Better Value Stock Right Now?
BLCO vs. AVTR: Which Stock Is the Better Value Option?
In Article Trend: Bullish
March 21, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
BLCO or AVTR: Which Is the Better Value Stock Right Now?
BLCO vs. AVTR: Which Stock Is the Better Value Option?
In Article Trend: Bullish
March 20, 2024 (16:20) / "Zacks Commentary" (by Zacks Equity Research)
Surging Earnings Estimates Signal Upside for Bausch + Lomb ( BLCO ) Stock
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
In Article Trend: Bullish
March 20, 2024 (06:30) / "GlobeNewswire" (by NICOX)
Results from Mont Blanc Phase 3 Trial of Nicox's NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
Press Release ...
In Article Trend: Neutral
March 20, 2024 (06:30) / "Benzinga" (by Globe Newswire)
Results from Mont Blanc Phase 3 Trial of Nicox's NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
Results from Mont Blanc Phase 3 Trial of Nicox's NCX 470 in Glaucoma Published in the American Journal of Ophthalmology First publication of the data from the Mont Blanc Phase 3 trial in a peer-reviewed journal Authors conclude: "NCX 470 could become an important first-line therapy for IOP ...
In Article Trend: Neutral
March 15, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Bausch Health ( BHC ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Somewhat-Bullish
March 13, 2024 (06:30) / "GlobeNewswire" (by NICOX)
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
Press Release ...
In Article Trend: Neutral
March 13, 2024 (06:30) / "Benzinga" (by Globe Newswire)
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 Focusing resources on the clinical development of Nicox's lead program NCX 470 in glaucoma NCX 470 Denali Phase 3 trial in patients with open-angle glaucoma or ocular hypertension on track ...
In Article Trend: Neutral
March 5, 2024 (06:30) / "GlobeNewswire" (by NICOX)
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
Press Release ...
In Article Trend: Neutral
March 5, 2024 (06:30) / "Benzinga" (by Globe Newswire)
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting March 5, 2024 - release at 7:30 am CET Sophia Antipolis, France
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website